Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Key Takeaways:

• Arcutis granted 61,000 RSUs to nine new hires
• Compliance with Nasdaq Listing Rule 5635(c)(4)
• Awards were approved by the Board’s Compensation Committee
• Grants issued under the 2022 Inducement Plan
• Move aligns with Arcutis’ strategy to expand in immuno-dermatology

Arcutis Biotherapeutics’ Focus on Innovation

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage biopharmaceutical company with a core dedication to developing meaningful innovations in immuno-dermatology. Its products and research efforts center on meeting crucial needs in skin health, positioning the company as a key player in this specialized field.

New Hires and the Inducement Plan

On July 1, 2026, Arcutis granted an aggregate of 61,000 restricted stock units (RSUs) to nine newly hired employees. These awards were issued under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, designed to encourage talented recruits to join and remain with the organization.

Approved by the Board’s Compensation Committee

The Compensation Committee of Arcutis’ Board of Directors granted the RSUs as a material inducement for the new employees, each of whom joined the company to bolster its research and commercial activities. The rigorous review and approval process ensured that these grants meet both company standards and regulatory mandates.

Nasdaq Listing Rule 5635(c)(4) Compliance

A key aspect of the announcement is alignment with Nasdaq Listing Rule 5635(c)(4). This rule ensures that equity compensation to newly hired employees meets transparent standards and reporting requirements. Arcutis’ adherence underscores the organization’s commitment to responsible corporate governance.

Looking Ahead

These inducement grants signal Arcutis’ broader strategy of fueling its workforce with skilled personnel who can drive the company’s mission forward. By blending innovation in immuno-dermatology with a competitive compensation framework, Arcutis aims to preserve its standing as a sought-after destination for top talent in the biotech field.